Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello D Bronstein

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Nature Reviews. Endocrinology|July 28, 2018
A Consensus Statement on acromegaly therapeutic outcomesShlomo Melmed, Marcello D Bronstein, Philippe Chanson, et al.
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
Pituitary|March 31, 2009
Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatmentAna Paula M Casarini, Raquel S Jallad, Emília M Pinto, et al.
European Journal of Endocrinology|March 29, 2020
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA studyAnnamaria Colao, Marcello D Bronstein, Thierry Brue, et al.
Molecular Cancer|January 16, 2007
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropesCarolina Cristina, Graciela S Díaz-Torga, Rodolfo G Goya, et al.
Clinics (Sao Paulo, Brazil)|June 20, 2013
PROP1 overexpression in corticotrophinomas: evidence for the role of PROP1 in the maintenance of cells committed to corticotrophic differentiationRicardo V Araujo, Claudia V Chang, Valter A S Cescato, et al.
BMC Endocrine Disorders|April 4, 2016
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III studyMarcello D Bronstein, Maria Fleseriu, Sebastian Neggers, et al.
European Journal of Endocrinology|June 7, 2015
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD studySebastian J C M M Neggers, Vyacheslav Pronin, Inga Balcere, et al.
Annales D'Endocrinologie|October 16, 2018
Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenomaPaulo V G H Amorim, Isabella P P Grande, Rafael L Batista, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2021
Impaired Bone Microarchitecture in Premenopausal Women With Acromegaly: The Possible Role of Wnt SignalingPaula P B Silva, Rosa M R Pereira, Liliam Takayama, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Nature Reviews. Endocrinology|July 28, 2018
A Consensus Statement on acromegaly therapeutic outcomesShlomo Melmed, Marcello D Bronstein, Philippe Chanson, et al.
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
Pituitary|March 31, 2009
Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatmentAna Paula M Casarini, Raquel S Jallad, Emília M Pinto, et al.
European Journal of Endocrinology|March 29, 2020
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA studyAnnamaria Colao, Marcello D Bronstein, Thierry Brue, et al.
Molecular Cancer|January 16, 2007
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropesCarolina Cristina, Graciela S Díaz-Torga, Rodolfo G Goya, et al.
Clinics (Sao Paulo, Brazil)|June 20, 2013
PROP1 overexpression in corticotrophinomas: evidence for the role of PROP1 in the maintenance of cells committed to corticotrophic differentiationRicardo V Araujo, Claudia V Chang, Valter A S Cescato, et al.
BMC Endocrine Disorders|April 4, 2016
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III studyMarcello D Bronstein, Maria Fleseriu, Sebastian Neggers, et al.
European Journal of Endocrinology|June 7, 2015
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD studySebastian J C M M Neggers, Vyacheslav Pronin, Inga Balcere, et al.
Annales D'Endocrinologie|October 16, 2018
Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenomaPaulo V G H Amorim, Isabella P P Grande, Rafael L Batista, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2021
Impaired Bone Microarchitecture in Premenopausal Women With Acromegaly: The Possible Role of Wnt SignalingPaula P B Silva, Rosa M R Pereira, Liliam Takayama, et al.
Pageof 10